Data is from Phase I/II clinical trial. (Eschbach et al, Am J Kidney Dis, 1987) See package insert for complete dosing information. As the hematocrit approaches 36%, reduce the dose of EPOGEN ® . The EPOGEN ® package insert recommends a target Hb (Hct) of 10 to 12 g/dL (30% to 36%).
• Patients who weigh more generally require higher starting doses than smaller patients, within the recommended EPOGEN ® starting dose range of 50 to 100 U/kg TIW • EPOGEN ® doses that may be adequate to elicit a timely and appropriate Hb response in some patients may not be adequate in other patients due to differences in bone marrow sensitivity 13 Achieve Hb levels in the NKF-K/DOQI™ target range of 11 to 12 g/dL* in a clinically appropriate time frame 
